INVENTISBIO: Re-Files for HKEX Listing; Two Core Products in Phase III and Two Products Commercialized

NewTimeSpace News: On 21 August 2026, InventisBio Co., Limited submitted a listing application to the Main Board of the Stock Exchange of Hong Kong, with CITIC SEC acting as the sole sponsor. Founded in 2013, the Company is a biopharmaceutical company focused on oncology, autoimmune diseases and metabolic disorders, with eight drug candidates in its portfolio, including two self-developed core products, D-2570 and taragarestrant (D-0502), both currently in Phase III clinical trials. The Company's A shares have been listed on the STAR Market of the Shanghai Stock Exchange since July 2022 (stock code: 688382).

According to the announcement, core product D-2570 is a tyrosine kinase 2 (TYK2) inhibitor for the treatment of autoimmune diseases including psoriasis, ulcerative colitis (UC), systemic lupus erythematosus (SLE), psoriatic arthritis (PsA) and vitiligo; taragarestrant (D-0502) is an oral selective estrogen receptor degrader (SERD) for the treatment of ER+/HER2- breast cancer. Both are undergoing registrational Phase III clinical trials, while the urate transporter 1 (URAT1) inhibitor darbinurad (D-0120) has completed a Phase IIb trial. In addition, the Company holds multiple preclinical candidates, including the Werner syndrome protein (WRN) inhibitor YF087, the kinesin family member 18A (KIF18A) inhibitor YF550 and the oral signal transducer and activator of transcription 6 (STAT6) degrader YF057.

In terms of commercialization, the Company's two products, the third-generation EGFR inhibitor befotertinib (BPI-D0316) and the KRAS G12C inhibitor garsorasib (D-1553), have been approved and launched in China and included in the National Reimbursement Drug List (NRDL), marking the Company's entry into the stage of commercial value realization.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.